Pedram, Kayvon http://orcid.org/0000-0001-8365-1826
Shon, D. Judy
Tender, Gabrielle S. http://orcid.org/0000-0002-3958-079X
Mantuano, Natalia R.
Northey, Jason J.
Metcalf, Kevin J.
Wisnovsky, Simon P.
Riley, Nicholas M.
Forcina, Giovanni C.
Malaker, Stacy A. http://orcid.org/0000-0003-2382-5067
Kuo, Angel
George, Benson M.
Miller, Caitlyn L. http://orcid.org/0000-0001-5120-7149
Casey, Kerriann M. http://orcid.org/0000-0003-4228-928X
Vilches-Moure, José G.
Ferracane, Michael J. http://orcid.org/0000-0002-3007-3126
Weaver, Valerie M. http://orcid.org/0000-0003-4786-6752
Läubli, Heinz
Bertozzi, Carolyn R. http://orcid.org/0000-0003-4482-2754
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA227942)
Article History
Received: 15 June 2022
Accepted: 22 May 2023
First Online: 3 August 2023
Competing interests
: A patent application relating to the use of targeted enzymes to digest mucin-domain glycoproteins has been filed by Stanford University (docket number STAN-1929PRV). C.R.B. is a co-founder and scientific advisory board member of Lycia Therapeutics, Palleon Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent), OliLux Bio, InterVenn Bio, GanNA Bio, Firefly Bio, Neuravid and Valora Therapeutics. H.L. received travel grants and consultant fees from Bristol-Myers Squibb (BMS) and Merck, Sharp and Dohme (MSD), Roche, InterVenn and Alector. H.L. received research support from BMS, Novartis, GlycoEra and Palleon Pharmaceuticals. The remaining authors declare no competing interests.